All Stories

  1. Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis

    Article • International Journal of Molecular Sciences, May 2026, MDPI AG

    Dr Cristina M Ramo-Tello

  2. Development of a New Patient-Reported Outcome to Measure Fatigue in Patients with Multiple Sclerosis

    Article • Nursing Reports, March 2026, MDPI AG

    Dr Cristina M Ramo-Tello

  3. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Article • Journal of Clinical Medicine, November 2023, MDPI AG

    Dr Cristina M Ramo-Tello

  4. Epstein-Barr Virus and Multiple Sclerosis: A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers

    Article • International Journal of Molecular Sciences, April 2023, MDPI AG

    Dr Cristina M Ramo-Tello

  5. Diagnostic confusion of demyelinating lesions and incidental diagnosis of a new pathogenic mutation of the FLNA gene

    Article • Neurología (English Edition), November 2022, Elsevier

    Dr Cristina M Ramo-Tello

  6. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Article • Neurology, October 2022, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  7. Gadolinium-enhanced brain lesions in multiple sclerosis relapse

    Article • Neurología (English Edition), September 2022, Elsevier

    Dr Cristina M Ramo-Tello

  8. Personalized Diagnosis and Therapy for Multiple Sclerosis

    Article • Journal of Personalized Medicine, June 2022, MDPI AG

    Dr Cristina M Ramo-Tello

  9. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis

    Article • Neurology, June 2022, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  10. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis

    Article • Neurology Neuroimmunology & Neuroinflammation, May 2022, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  11. Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

    Article • Journal of Clinical Medicine, April 2022, MDPI AG

    Dr Cristina M Ramo-Tello

  12. Catastrophic demyelinating multifocal encephalitis

    Article • Neurología (English Edition), March 2022, Elsevier

    Dr Cristina M Ramo-Tello

  13. Encefalitis desmielinizante multifocal catastrófica

    Article • Neurología, March 2022, Elsevier

    Dr Cristina M Ramo-Tello

  14. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]

    Article • Computer Methods and Programs in Biomedicine, January 2022, Elsevier

    Dr Cristina M Ramo-Tello

  15. Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses

    Article • Journal of Personalized Medicine, December 2021, MDPI AG

    Dr Cristina M Ramo-Tello

  16. Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab

    Article • Journal of Personalized Medicine, December 2021, MDPI AG

    Dr Cristina M Ramo-Tello

  17. Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis

    Article • Biomedicines, November 2021, MDPI AG

    Dr Cristina M Ramo-Tello

  18. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

    Article • The Lancet Neurology, November 2021, Elsevier

    Dr Cristina M Ramo-Tello

  19. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Article • Computer Methods and Programs in Biomedicine, September 2021, Elsevier

    Dr Cristina M Ramo-Tello

  20. Lesión pseudotumoral única, una presentación de inicio infrecuente del trastorno del espectro de la neuromielitis óptica

    Article • Neurología, June 2021, Elsevier

    Dr Cristina M Ramo-Tello

  21. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

    Article • Cellular and Molecular Immunology, May 2021, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  22. Single pseudotumour lesion, a rare debut presentation of optic neuromyelitis spectrum disorder

    Article • Neurología (English Edition), March 2021, Elsevier

    Dr Cristina M Ramo-Tello

  23. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

    Article • Neurology, February 2021, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  24. Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS

    Article • Multiple Sclerosis and Related Disorders, February 2021, Elsevier

    Dr Cristina M Ramo-Tello

  25. Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness

    Article • Frontiers in Immunology, January 2021, Frontiers

    Dr Cristina M Ramo-Tello

  26. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

    Article • Neurology, January 2021, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  27. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

    Article • Frontiers in Neurology, December 2020, Frontiers

    Dr Cristina M Ramo-Tello

  28. Single cell profiling of COVID-19 patients: an international data resource from multiple tissues

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Dr Cristina M Ramo-Tello

  29. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Article • Brain, September 2020, Oxford University Press (OUP)

    Dr Cristina M Ramo-Tello

  30. Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

    Article • Multiple Sclerosis Journal - Experimental Translational and Clinical, July 2020, SAGE Publications

    Dr Cristina M Ramo-Tello

  31. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

    Article • Multiple Sclerosis Journal, June 2020, SAGE Publications

    Dr Cristina M Ramo-Tello

  32. Early clinical markers of aggressive multiple sclerosis

    Article • Brain, May 2020, Oxford University Press (OUP)

    Dr Cristina M Ramo-Tello

  33. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

    Article • Journal of Neurology Neurosurgery & Psychiatry, March 2020, BMJ

    Dr Cristina M Ramo-Tello

  34. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

    Article • BMJ Open, September 2019, BMJ

    Dr Cristina M Ramo-Tello

  35. Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years

    Article • August 2019, Cold Spring Harbor Laboratory Press

    Dr Cristina M Ramo-Tello

  36. Early clinical markers of aggressive multiple sclerosis

    Article • July 2019, Cold Spring Harbor Laboratory Press

    Dr Cristina M Ramo-Tello

  37. Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment

    Article • Mediators of Inflammation, June 2019, Hindawi Publishing Corporation

    Dr Cristina M Ramo-Tello

  38. MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients

    Article • Frontiers in Immunology, June 2019, Frontiers

    Dr Cristina M Ramo-Tello

  39. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

    Article • Trials, May 2019, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  40. Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

    Article • CNS Neuroscience & Therapeutics, May 2019, Wiley

    Dr Cristina M Ramo-Tello

  41. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Article • Multiple Sclerosis and Related Disorders, February 2019, Elsevier

    Dr Cristina M Ramo-Tello

  42. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

    Article • Journal of Neurology Neurosurgery & Psychiatry, January 2019, BMJ

    Dr Cristina M Ramo-Tello

  43. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial

    Article • European Journal of Neurology, November 2018, Wiley

    Dr Cristina M Ramo-Tello

  44. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

    Article • European Journal of Neurology, November 2018, Wiley

    Dr Cristina M Ramo-Tello

  45. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

    Article • JAMA Neurology, November 2018, American Medical Association (AMA)

    Dr Cristina M Ramo-Tello

  46. Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin

    Article • Scientific Reports, October 2018, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  47. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

    Article • CNS Neuroscience & Therapeutics, April 2018, Wiley

    QUIRANT BIBIANA, Dr Cristina M Ramo-Tello

  48. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

    Article • Multiple Sclerosis Journal, October 2017, SAGE Publications

    Dr Cristina M Ramo-Tello

  49. Hepatitis tóxica tras tratamiento concomitante con interferón beta y aloe vera en un paciente con esclerosis múltiple: a propósito de un caso

    Article • Neurología, October 2017, Elsevier

    Dr Cristina M Ramo-Tello

  50. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

    Article • Neurology, August 2017, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  51. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

    Article • Brain, August 2017, Oxford University Press (OUP)

    Dr Cristina M Ramo-Tello

  52. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients

    Article • Cytometry Part B Clinical Cytometry, April 2017, Wiley

    Dr Cristina M Ramo-Tello

  53. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2017, New England Journal of Medicine (NEJM/MMS)

    Dr Cristina M Ramo-Tello, Professor Tjalf Ziemssen

  54. Defining secondary progressive multiple sclerosis

    Article • Brain, July 2016, Oxford University Press (OUP)

    Dr Tomas Kalincik, Dr Cristina M Ramo-Tello

  55. Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients

    Article • Journal of Neuroinflammation, May 2016, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  56. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients

    Article • CNS Neuroscience & Therapeutics, April 2016, Wiley

    Dr Cristina M Ramo-Tello

  57. Neuromyelitis optica spectrum disorders

    Article • Neurology Neuroimmunology & Neuroinflammation, April 2016, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  58. Mielitis. Diferencias entre esclerosis múltiple y otras etiologías

    Article • Neurología, March 2016, Elsevier

    Dr Cristina M Ramo-Tello

  59. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients

    Article • Autoimmunity, February 2016, Taylor & Francis

    Dr Cristina M Ramo-Tello

  60. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen

    Article • Neurodegenerative Disease Management, October 2015, Future Medicine

    Dr Cristina M Ramo-Tello

  61. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses

    Article • Multiple Sclerosis Journal, June 2015, SAGE Publications

    Dr Cristina M Ramo-Tello

  62. Beneficial Effect of Tolerogenic Dendritic Cells Pulsed with MOG Autoantigen in Experimental Autoimmune Encephalomyelitis

    Article • CNS Neuroscience & Therapeutics, November 2014, Wiley

    Dr Cristina M Ramo-Tello

  63. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses

    Article • Multiple Sclerosis Journal, August 2014, SAGE Publications

    Dr Cristina M Ramo-Tello

  64. Encefalopatía y neuromielitis óptica: importancia del reconocimiento de la sintomatología atípica

    Article • Revista de Neurología, January 2014, IMR Press

    Dr Cristina M Ramo-Tello

  65. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

    Article • Multiple Sclerosis Journal, October 2013, SAGE Publications

    Dr Cristina M Ramo-Tello

  66. Lesión del núcleo del trigémino por virus herpes simple

    Article • Revista de Neurología, January 2013, IMR Press

    Dr Cristina M Ramo-Tello

  67. Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients

    Article • BMC Neurology, September 2012, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  68. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients

    Article • European Journal of Immunology, March 2012, Wiley

    Dr Cristina M Ramo-Tello

  69. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice

    Article • Journal of Immunological Methods, August 2011, Elsevier

    Dr Cristina M Ramo-Tello

  70. Análisis del dolor en pacientes con esclerosis múltiple

    Article • Neurología, May 2011, Elsevier

    Dr Cristina M Ramo-Tello

  71. Adherence to Disease-Modifying Therapies in Spanish Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence Project

    Article • European Neurology, January 2011, Karger Publishers

    Dr Cristina M Ramo-Tello

  72. Comparative study of clinical grade human tolerogenic dendritic cells

    Article • Journal of Translational Medicine, January 2011, Springer Science + Business Media

    Dr Cristina M Ramo-Tello

  73. HLA-DRB1 en pacientes caucásicos con neuromielitis óptica

    Article • Revista de Neurología, January 2011, IMR Press

    Dr Cristina M Ramo-Tello

  74. Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis

    Article • European Journal of Neurology, December 2010, Wiley

    Dr Cristina M Ramo-Tello

  75. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

    Article • European Journal of Neurology, December 2010, Wiley

    Dr Cristina M Ramo-Tello, Prof Roy G Beran

  76. Transverse Myelitis Affecting More Than 4 Spinal Segments Associated with Systemic Lupus Erythematosus: Clinical, Immunological, and Radiological Characteristics of 22 Patients

    Article • Seminars in Arthritis and Rheumatism, February 2010, Elsevier

    Dr Cristina M Ramo-Tello

  77. Situación epidemiológica actual de la esclerosis múltiple: pertinencia y puesta en marcha de un registro poblacional de nuevos casos en Cataluña

    Article • Revista de Neurología, January 2010, IMR Press

    Dr Cristina M Ramo-Tello

  78. Myelin peptides in multiple sclerosis

    Article • Autoimmunity Reviews, July 2009, Elsevier

    Dr Cristina M Ramo-Tello

  79. Evaluation of the Anti-HIV Activity of Natalizumab—An Antibody Against Integrin alpha4

    Article • Antiviral Research, May 2009, Elsevier

    Dr Cristina M Ramo-Tello

  80. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4

    Article • AIDS, January 2009, Wolters Kluwer Health

    Dr Cristina M Ramo-Tello

  81. S.41. Specific T Cell Proliferative Response in Patients with Relapsing-remitting Multiple Sclerosis to a Definite Group of Myelin Peptides

    Article • Clinical Immunology, January 2009, Elsevier

    Dr Cristina M Ramo-Tello

  82. ¿Qué tratamiento debemos emplear actualmente en la esclerosis múltiple?

    Article • Revista de Neurología, January 2000, IMR Press

    Dr Cristina M Ramo-Tello

  83. Familial cosegregation of manic‐depressive illness and a form of hereditary cerebellar ataxia

    Article • American Journal of Medical Genetics, June 1995, Wiley

    Dr Cristina M Ramo-Tello